Comparative Pharmacology
Head-to-head clinical analysis: HIPREX versus UROBAK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIPREX versus UROBAK.
HIPREX vs UROBAK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hippuric acid, the active metabolite of methenamine, acidifies urine and releases formaldehyde, which denatures bacterial proteins and nucleic acids, bactericidal activity requires acidic urine (pH < 5.5).
UROBAK (methenamine hippurate) is a prodrug that hydrolyzes to formaldehyde in acidic urine (pH ≤ 5.5). Formaldehyde denatures bacterial proteins and nucleic acids, exerting a broad-spectrum bacteriostatic effect. The hippurate component may enhance urinary acidification.
1 gram orally twice daily (every 12 hours) with meals
500 mg orally once daily
None Documented
None Documented
3-6 hours (methenamine); clinical context: prolonged in renal impairment, requiring dose adjustment.
6-8 hours (prolonged in renal impairment).
Renal excretion: >90% as unchanged drug (methenamine) and formaldehyde; biliary/fecal: <5%.
Primarily renal (85% unchanged); 15% biliary/fecal.
Category C
Category C
Urinary Anti-infective
Urinary Anti-infective